HK1257466A2 - 皮膚病的藥物製劑 - Google Patents

皮膚病的藥物製劑

Info

Publication number
HK1257466A2
HK1257466A2 HK18108035A HK18108035A HK1257466A2 HK 1257466 A2 HK1257466 A2 HK 1257466A2 HK 18108035 A HK18108035 A HK 18108035A HK 18108035 A HK18108035 A HK 18108035A HK 1257466 A2 HK1257466 A2 HK 1257466A2
Authority
HK
Hong Kong
Prior art keywords
drug formulation
dermal diseases
dermal
diseases
formulation
Prior art date
Application number
HK18108035A
Other languages
English (en)
Inventor
Ka Wing Cheng
Wing Chi Tang
Koon Chung Hui
Original Assignee
Master Dynamic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Master Dynamic Ltd filed Critical Master Dynamic Ltd
Priority to HK18108035A priority Critical patent/HK1257466A2/zh
Priority to CN201980041247.9A priority patent/CN112292152A/zh
Priority to US17/254,685 priority patent/US20210268123A1/en
Priority to EP19822662.3A priority patent/EP3810202A4/en
Priority to PCT/CN2019/092173 priority patent/WO2019242706A1/en
Publication of HK1257466A2 publication Critical patent/HK1257466A2/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18108035A 2018-06-22 2018-06-22 皮膚病的藥物製劑 HK1257466A2 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
HK18108035A HK1257466A2 (zh) 2018-06-22 2018-06-22 皮膚病的藥物製劑
CN201980041247.9A CN112292152A (zh) 2018-06-22 2019-06-21 皮肤病用药物制剂
US17/254,685 US20210268123A1 (en) 2018-06-22 2019-06-21 Drug formulation for dermal diseases
EP19822662.3A EP3810202A4 (en) 2018-06-22 2019-06-21 DRUG FORMULATION FOR DERMAL DISEASES
PCT/CN2019/092173 WO2019242706A1 (en) 2018-06-22 2019-06-21 Drug formulation for dermal diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HK18108035A HK1257466A2 (zh) 2018-06-22 2018-06-22 皮膚病的藥物製劑

Publications (1)

Publication Number Publication Date
HK1257466A2 true HK1257466A2 (zh) 2019-10-18

Family

ID=68465536

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108035A HK1257466A2 (zh) 2018-06-22 2018-06-22 皮膚病的藥物製劑

Country Status (5)

Country Link
US (1) US20210268123A1 (zh)
EP (1) EP3810202A4 (zh)
CN (1) CN112292152A (zh)
HK (1) HK1257466A2 (zh)
WO (1) WO2019242706A1 (zh)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799593B2 (en) * 2008-06-09 2020-10-13 Northwestern University Nanodiamond particle complexes
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
EP3265961A1 (en) * 2015-03-02 2018-01-10 Taaneh, Inc. Authenticated systems employing fluorescent diamond particles
CN105949733B (zh) * 2016-05-24 2018-02-13 河北工业大学 一种温敏型嵌段共聚物修饰纳米金刚石的方法
CN107929242B (zh) * 2017-11-26 2020-01-07 郑州大学 基于纳米金刚石的药物载体、药物复合体及其制备方法和应用

Also Published As

Publication number Publication date
CN112292152A (zh) 2021-01-29
US20210268123A1 (en) 2021-09-02
EP3810202A1 (en) 2021-04-28
EP3810202A4 (en) 2022-04-20
WO2019242706A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
CL2020003174S1 (es) Dispositivo para administración de dosis.
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
PH12020551934A1 (en) Magl inhibitors
PH12019501076A1 (en) Pharmaceutical formulations
PH12019500061A1 (en) Oral gastroretentive formulations and uses thereof
PH12016501841A1 (en) Immunosuppressant formulation
PH12019502548A1 (en) Pyrazole magl inhibitors
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
MX2021005038A (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas.
CL2019002808A1 (es) Métodos para prevenir o tratar enfermedades oftálmicas.
HK1257466A2 (zh) 皮膚病的藥物製劑
MX2020007627A (es) Uso de la carrimicina o de sus ingredientes activos.
IN2013MU03370A (zh)
MX2020010938A (es) Medicamento para prevenir y/o tratar el dolor y/o la fiebre, producto compuesto y uso del mismo.
HK1257783A2 (zh) 皮膚病的藥物製劑
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
MX2020006886A (es) Sistema para suministro de medicamento.
CL2016003271A1 (es) Métodos para tratar infecciones
MX2021012146A (es) Formulacion de tableta vaginal.
ZA202105718B (en) Novel composition